PRNewsWire
02 Jul 2026, 00:11 UTC · 11w ago
Verdict
Headline takes no side. We score LRMR −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Larimar Therapeutics' nomlabofusp study revealed a significant safety signal with anaphylaxis reported in 10 out of 43 patients.
More negative than 99% of claims this week
Pomerantz LLP is investigating Larimar Therapeutics for potential securities fraud and unlawful business practices.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 91% of claims this week
Larimar Therapeutics has submitted the first section of its rolling Biologics License Application (BLA) for nomlabofusp.
More positive than 63% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is being investigated for securities fraud following severe allergic reactions in clinical trials and significant stock price drops.
More negative than 85% of ticker scores this week
The company is the subject of an investigation by Pomerantz Law Firm on behalf of investors.
More negative than 85% of ticker scores this week
The company is the subject of an investigation by Pomerantz Law Firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
4h ago
+20.4%
Price is moving against the score
$3.87 vs $3.21 close before publication (Jul 1) · not market-adjusted
LRMR chart →
